About bimekizuma b
Interleukin-17A and IL-17F inhibitor
Used for
- Moderate-to-severe plaque psoriasis in eligible adults
- Active psoriatic arthritis in adults
- Axial spondyloarthritis in adults
- Hidradenitis suppurativa in adults
Usual adult dose
Usually 320 mg under the skin every four weeks initially for psoriasis or hidradenitis; maintenance timing varies. Other conditions commonly use 160 mg every four weeks.
Common side effects
- Upper respiratory infections, such as colds
- Oral thrush and other fungal infections
- Injection-site reactions
- Headache
Important warnings
- Do not start during a serious active infection.
- Screen for tuberculosis before treatment; monitor for infection.
- May worsen inflammatory bowel disease, including Crohn’s disease or ulcerative colitis.
- Avoid live vaccines during treatment.
Pregnancy
Human pregnancy information is limited; use only when clearly needed after assessing benefits and risks.
Breastfeeding
It is unknown whether bimekizumab passes into breast milk; consider treatment benefits and potential infant risks.
Interactions
- Live vaccines may cause infection and should be avoided.
- Other biologic immune-modifying medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.